Evidence map›Paper›PMID 40213938›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

DNA Molecular Computing with Weighted Signal Amplification for Cancer miRNA Biomarker Diagnostics.

Hongyang Zhao, Yumin Yan, Linghao Zhang, Xin Li, Lan Jia, Liang Ma, Xin Su

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hongyang ZhaoState Key Laboratory of Organic-Inorganic Composites, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.
Yumin YanState Key Laboratory of Organic-Inorganic Composites, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.
Linghao ZhangState Key Laboratory of Organic-Inorganic Composites, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.
Xin LiDepartment of thoracic surgery, Tianjin Chest Hospital, Tianjin, 300222, China.
Lan JiaDepartment of Kidney Disease and Blood Purification, The Second Hospital of Tianjin, Medical University, Tianjin, 300211, China.
Liang MaClinical Laboratory, China-Japan Friendship Hospital, Beijing, 100029, China.
Xin SuState Key Laboratory of Organic-Inorganic Composites, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.ORCID https://orcid.org/0000-0002-6629-9856

Funding

Fundamental Research Funds for the Central Universities PT2406National Natural Science Foundation of China 31971361National Natural Science Foundation of China 32271521Natural Science Foundation of Tianjin Municipal Science and Technology Commission 31971361Natural Science Foundation of Tianjin Municipal Science and Technology Commission 32271521Natural Science Foundation of Tianjin Municipal Science and Technology Commission 82170763State Key Laboratory of Natural and Biomimetic Drugs K202427State Key Research Development Program of China 2022YFC2603902
6 · The paper itself

Abstract

The expression levels of microRNAs (miRNAs) are strongly linked to cancer progression, making them promising biomarkers for cancer detection. Enzyme-free signal amplification DNA circuits have facilitated the detection of low-abundance miRNAs. However, these methods may neglect the diagnostic value (or weight) of different miRNAs. Here, a molecular computing approach with weighted signal amplification is presented. Polymerase-mediated strand displacement is employed to assign weights to target miRNAs, reflecting the miRNAs' diagnostic values, followed by amplification of the weighted signals using localized DNA catalytic hairpin assembly. This method is applied to diagnose miRNAs for non-small cell lung cancer (NSCLC). Machine learning is used to identify NSCLC-specific miRNAs and assign corresponding weights for optimum classification of healthy and lung cancer individuals. With the molecular computing of the miRNAs, the diagnostic output is simplified as a single channel of fluorescence intensity. Cancer tissues (n = 18) and adjacent cancer tissues (n = 10) are successfully classified within 2.5 h (sample-to-result) with an accuracy of 92.86%. The weighted amplification strategy has the potential to extend to the digital detection of multidimensional biomarkers, advancing personalized disease diagnostics in point-of-care settings.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungComputers, MolecularLung NeoplasmsMicroRNAsHumansMachine LearningBiomarkers, TumorMicroRNAsDNA computingmachine learningmiRNANSCLC diagnosticssignal amplification

Identifiers

PMID40213938
PMCPMC12165086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.